Previous
Previous

K36 Therapeutics Completes Dosing of First Cohort in PCCTC-Managed Phase 1 Clinical Trial of KTX-2001 in Prostate Cancer

Next
Next

PCCTC Investigator Dr George on the Role of Radioligand Therapy in Prostate Cancer Management